Frontiers in immunology · 2026
BFJPM ameliorates OVA-induced food allergy in a murine model accompanied by gut microbiota remodeling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Xue, Peng Huiyi, Hu Rao, Li Yifan, Jiang Ping
Аннотация
UNLABELLED: BufeiJianpi Mixture (BFJPM) is a modified herbal formula developed from long-term clinical practice for the management of allergic constitution in children. To evaluate the therapeutic efficacy of BFJPM in an OVA-induced murine model of food allergy and to investigate its effects on the gut microbiota through integrated animal experiments, 16S rRNA gene sequencing, and network pharmacology.
METHODS: Sixty 3-week-old female BALB/c mice were randomly assigned to six groups: negative control (NC), FA model, cetirizine, BFJPM-L, BFJPM-M, and BFJPM-H. An OVA-induced food allergy model was established. Therapeutic efficacy was assessed using allergy symptom scores, the V/C ratio of the small intestinal mucosa, and serum total IgE levels. Gut microbiota profiles were analyzed by 16S rRNA sequencing of intestinal contents. PICRUSt2 was used to predict microbial functional profiles, and network pharmacology was applied to identify key targets and pathways involved in BFJPM-mediated intervention.
RESULTS: BFJPM reduced allergy symptom scores and serum total IgE levels and improved the V/C ratio in FA mice. NMDS analysis showed significant differences in gut microbiota composition among groups (stress = 0.141). BFJPM increased microbial richness and altered community structure, with enrichment of Actinobacteria and Candidatus Arthromitus. Among the differential taxa, Saccharopolyspora emerged as the most promising genus associated with BFJPM intervention and was negatively correlated with serum IgE levels. Integrated network pharmacology and microbial functional prediction identified IL6, TNF, and IL10 as major targets of BFJPM in FA. The African trypanosomiasis pathway was identified as a shared pathway linking BFJPM, FA, and gut microbiota-associated functional alterations.
CONCLUSION: BFJPM alleviated food allergy symptoms, reduced serum IgE levels, and improved intestinal mucosal integrity in OVA-induced FA mice. These effects were accompanied by remodeling of the gut microbiota. Saccharopolyspora may represent a microbial feature associated with BFJPM treatment. The African trypanosomiasis pathway may indicate a potential point of convergence between BFJPM-regulated host pathways and microbiota-associated functional changes. However, the causal relationship between microbiota remodeling and therapeutic efficacy remains to be established.
METHODS: Sixty 3-week-old female BALB/c mice were randomly assigned to six groups: negative control (NC), FA model, cetirizine, BFJPM-L, BFJPM-M, and BFJPM-H. An OVA-induced food allergy model was established. Therapeutic efficacy was assessed using allergy symptom scores, the V/C ratio of the small intestinal mucosa, and serum total IgE levels. Gut microbiota profiles were analyzed by 16S rRNA sequencing of intestinal contents. PICRUSt2 was used to predict microbial functional profiles, and network pharmacology was applied to identify key targets and pathways involved in BFJPM-mediated intervention.
RESULTS: BFJPM reduced allergy symptom scores and serum total IgE levels and improved the V/C ratio in FA mice. NMDS analysis showed significant differences in gut microbiota composition among groups (stress = 0.141). BFJPM increased microbial richness and altered community structure, with enrichment of Actinobacteria and Candidatus Arthromitus. Among the differential taxa, Saccharopolyspora emerged as the most promising genus associated with BFJPM intervention and was negatively correlated with serum IgE levels. Integrated network pharmacology and microbial functional prediction identified IL6, TNF, and IL10 as major targets of BFJPM in FA. The African trypanosomiasis pathway was identified as a shared pathway linking BFJPM, FA, and gut microbiota-associated functional alterations.
CONCLUSION: BFJPM alleviated food allergy symptoms, reduced serum IgE levels, and improved intestinal mucosal integrity in OVA-induced FA mice. These effects were accompanied by remodeling of the gut microbiota. Saccharopolyspora may represent a microbial feature associated with BFJPM treatment. The African trypanosomiasis pathway may indicate a potential point of convergence between BFJPM-regulated host pathways and microbiota-associated functional changes. However, the causal relationship between microbiota remodeling and therapeutic efficacy remains to be established.